Car T Cell Therapy Market Analysis
CAR T Cell Therapy Market, By Targeted Antigen (HER1, HER2, GD2, BCMA,CD20, CD19, CD22, CD30, CD33, Others (CLDN18, etc.)), By Therapeutic Application (Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Follicular Lymphoma, Glioblastoma, Multiple Myeloma, Hepatocellular Carcinoma, Sarcoma, Acute Myeloid Leukemia, Neuroblastoma, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Others (Gastric Cancer, etc.)), and By Region (Africa, Latin America, Asia Pacific, the Middle East, Europe, North America) – Size, Outlook, Share, and Opportunity Analysis, 2022–2030
Request a sample copy of this report @ Click here: – https://www.coherentmarketinsights.com/insight/request-sample/102
Chimeric antigen receptor—T, i.e., CAR T cell therapy, is a form of gene cell therapy that utilizes T cells to attack cancer cells. The process involves three main stages, including collecting T cells, modifying them through engineering, and then introducing the CAR T cells back into the body. This approach is T-cell immunotherapy, which harnesses the body’s own immune system to combat cancer. A significant risk associated with CAR T cell therapy is cytokine release syndrome (CRS), which occurs when CAR T cells release cytokines, triggering immune responses such as fever, fatigue, diarrhea, chills, nausea, difficulty breathing, low blood pressure, and other symptoms.
The global CAR T cell therapy market is projected to reach a value of US$ 2,259.5 million by 2022 growing at a CAGR of 20.9 % during the forecast period from 2022 to 2030.
The global CAR T cell therapy market is anticipated to experience growth during the forecast period due to the rising incidence of cancer. As an illustration, in February 2022, the World Health Organization (WHO) released a fact sheet indicating that approximately 400,000 children are diagnosed with cancer every year and there were 2.26 million cases of breast cancer worldwide in 2021.
During the forecast period, the global CAR T cell therapy market is anticipated to experience growth due to major companies prioritizing product approval. For example, in April 2022, Kite Pharma, Inc., which is a subsidiary of Gilead Sciences, Inc. and a research-based biopharmaceutical company focused on developing innovative medicines, received approval from the U.S. Food and Drug Administration for Yescarta as an initial treatment for relapsed or refractory large B-cell lymphoma (LBCL).
Impact of the Coronavirus (COVID-19) Pandemic
The disease caused by the COVID-19 virus has spread to more than 100 countries worldwide since it first emerged in December 2019, and on January 30, 2020, the World Health Organization declared it a public health emergency.
The economy has been impacted by COVID-19 in three major ways, including the direct influence on drug and vaccine production and demand, the disruptions caused in distribution channels, and the financial repercussions on firms and financial markets. Countries including India, Egypt, Saudi Arabia, China, the U.A.E., and others experienced challenges in transporting vaccines and drugs due to nationwide lockdowns. Since the emergence of the COVID-19 pandemic in December 2019, it has rapidly spread to over 100 countries, leading the World Health Organization to declare it a public health emergency. As of November 15, 2022, a report published by the World Health Organization indicates that COVID-19 has caused more than 632,533,408 confirmed cases worldwide.
Additionally, cancer patients are greatly affected by the COVID-19 pandemic as it pertains to the implementation of CAR T cell therapy for SARS-CoV-2. In April 2020, Duke-NUS, a school of the National University of Singapore, released data which suggested that CAR T cell therapy could be utilized for the management of SARS-CoV-2 and other infectious diseases.
Buy Now, Getting Exclusive (Up To 45% Discount) click here @ https://www.coherentmarketinsights.com/promo/buynow/102
Bristol-Myers Squibb Company, a prominent biopharmaceutical company, received US Food and Drug Administration approval for Breyanzi CAR T cell therapy in June 2022. This therapy is intended for treating large B-cell lymphoma in patients who have experienced relapse or have not responded to prior treatment. The approval was granted after the Phase 2 pilot company-sponsored study, which evaluated the effectiveness of CAR T cell therapy in patients with primary refractory or relapsed LBCL.
CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR T immunotherapy for treating patients with relapsed or refractory multiple myeloma, was approved by the US Food and Drug Administration in February 2022. This breakthrough was announced by Johnson & Johnson Services, Inc., which is one of the biggest healthcare companies.
The primary obstacle to the expansion of the global CAR T cell therapy market is the adverse effects of this treatment. In March 2022, the American Cancer Society, a nationwide voluntary health organization, released data indicating that numerous potential side effects may arise from CAR T cell therapy, including high fever, respiratory difficulties, chills, vomiting, severe nausea, diarrhea, dizziness or lightheadedness, rapid heartbeat, headaches, fatigue, as well as muscle and joint pain.
Some of the major companies in the global CAR T cell therapy market consist of Sorrento Therapeutics, Inc., Pfizer Inc., Bristol-Myers Squibb Company, Fate Therapeutics, Johnson & Johnson Services Inc., Bluebird Bio, Inc., Novartis AG, Gilead Sciences, Inc., CARsgen Therapeutics Co., Ltd., Legend Biotech, Mustang Bio, and Aurora Biopharma.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Targeted Antigen
- Market Snapshot, By Therapeutic Application
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Regulatory Scenario
- Pipeline Analysis
- PEST Analysis
- Porter’s Analysis
- Market Dynamics
Get your Customized Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/102
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭𝐬
Plasmid dna manufacturing market
Gmp protein e coli contract manufacturing market
Stem cell manufacturing market
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States
Phone: U.S.: +1-206-701-6702